TABLE 1 

Seroprevalence rates in cases and controls

PathogenSeroprevalence
cases (%)
95% CIaSeroprevalence
controls (%)
95% CIOdds
ratiob
95% CIPd
ZIKV93.878.8–99.367.859.9–74.87.1c1.6–31.10.002
CHIKV20.79.5–38.88.25.2–14.82.9c1.0–8.40.039
DENV74.155.1–87.189.179.2–95.60.30.0–1.00.100
RUBV90.675.0–97.597.593.5–99.20.20.0–1.20.092
HSV-193.878.8–99.395.090.3–97.60.80.1–3.90.673
HSV-228.115.4–45.547.132.1–47.10.60.3–1.40.230
VZV87.571.3–95.694.489.5–97.20.40.1–1.50.236
CMV96.982.9–100.096.992.7–99.01.00.1–8.91.000
PV-B1931.317.8–48.735.628.6–43.30.80.4–1.80.635
C. trachomatis46.930.9–63.648.140.5–55.80.90.4–2.00.897
B. pertussis56.339.3–71.959.451.8–66.70.90.4–1.90.742
T. pallidum0.00.0–9.31.30.0–4.70.90.0–20.81.000
T. gondii53.136.5–69.158.751.0–66.10.80.4–1.70.556
  • a CI, confidence interval.

  • b Data represent results from bivariate comparisons.

  • c In conditional logistic regression analyses, odds ratios were as follows: ZIKV (P = 0.030; odds ratio, 4.0 [95% CI, 1.1 to 14.1]) and CHIKV (P = 0.084; odds ratio, 2.8 [95% CI, 0.1 to 9.2]).

  • d Data were calculated using χ2 tests and Fisher’s exact tests when any cell count was below 5. Bold type denotes statistical significance.